title: Why are investors not interested in my radiotracer? The industrial and regulatory constraints in the development of radiopharmaceuticals.
abstract: Four criteria are essential in the acceptance by investors of new radiopharmaceuticals: the existence of a market and a medical need, the quality of the science and technology behind the new molecule, the feasibility and compliance with regulations and the limited competitive landscape. Potential investors need to get more convincing market evidence, largely beyond the nice preclinical data generated to the point of first discussion. A properly protected compound not jeopardized by earlier published results is a must. A guarantee of an easy and secured source of the ligand is obvious. A safe access to the radionuclide in volumes corresponding to the targeted market is rarely taken into account, but of utmost importance. The evaluation of new drugs by investors will include the evaluation of the real market size for the targeted indication and the position of the drug in the healthcare environment at the time to market. This includes the potential competition with other radiopharmaceuticals, but also with conventional drugs or competitive modalities also at time to market. Both criteria are usually not easily accessible to researchers whose acquaintance remains limited to the scientific and technical part. Starting from this set of information, a first business plan can be deduced based on a best estimate for price per dose and a rough evaluation about the chance and level of reimbursement. In the following most of the events are covered that could jeopardize the development of the drug, focusing on the industrial, economic and regulatory aspects, comprehending the detailed analysis of the currently best available radionuclides.
authors.affiliation: Chrysalium Consulting SARL, 78470 Saint Rémy lès Chevreuse, France. richard.zimmermann@chrysalium.com
authors.forename: Richard G
authors.initials: RG
authors.lastname: Zimmermann
mesh_terms: D000818:Animals; D055808:Drug Discovery / Q000191:economics*; D004345:Drug Industry / Q000191:economics*; D006801:Humans; D007449:Investments / Q000706:statistics & numerical data*; D011849:Radioactive Tracers; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000737:chemistry / Q000191:economics* / Q000494:pharmacology; D012926:Social Control, Formal
chemical_list: D011849:Radioactive Tracers; D019275:Radiopharmaceuticals